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background: Randomized controlled trials examining warfarin use for stroke prevention in atrial fibrillation (AF) may not accurately reflect real-
world populations.
methods: The inclusion and exclusion criteria, patient characteristics, and clinical outcomes from RE-LY, ROCKET-AF, and ARISTOTLE were compared 
against data from a regional network of seven community- and academic-based anticoagulation clinics in Michigan (MAQI2).
results: Of the 3097 non-valvular AF patients in the MAQI2 registry taking warfarin, approximately half or fewer would meet the selection criteria 
used in RE-LY (1589, 51.3%), ROCKET-AF (1002, 32.4%), and ARISTOTLE (1719, 55.5%). The most common reason for exclusion from one or more 
trial populations was planned cardioversion (24.7%), ablation (15.5%) or other concurrent medications (15.0%). Trial-eligible MAQI2 patients were 
older, more frequently female, with a higher rate of paroxysmal AF, less heart failure, lower rate of previous stroke and less prior myocardial infarction 
than the actual trial populations (Table). MAQI2 patients eligible for ROCKET-AF had lower mean CHADS2 score than the trial population, while those 
eligible for RE-LY and ARISTOTLE had mean CHADS2 scores similar to the trial populations. MAQI2 patients eligible for each trial had a lower rate of 
stroke and similar rate of major bleeding than was observed in the trials.
conclusion: Real-world AF patients on warfarin may have a lower stroke risk than is observed in randomized controlled trials.
